Tresidder published BioCity firm sold for £8m

Haemostatix, a Nottingham company specialising in clotting agents, has been sold by venture capital owners for £8 million. Haemostatix, based in BioCity on Pennyfoot Street, is a specialist in developing first-in-class topical clotting agents and was founded by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester.The technology is based on a novel class of molecule that binds directly to fibrinogen to promote haemostasis and is targeted at the...